Olodaterol

Drug Profile

Olodaterol

Alternative Names: BI-1744; BI-1744-CL; BI1774CL; Olodaterol hydrochloride; Striverdi Respimat

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Ketones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 28 Oct 2014 Efficacy and adverse events data from the ANHELTO 1 and 2 phase III trials in Chronic obstructive pulmonary disease presented at the 80th Annual Meeting of the American College of Chest Physicians (ACCP-2014)
  • 09 Oct 2014 Launched for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Aug 2014 Registered for Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top